Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome

Idiopathic nephrotic syndrome resistant to standard treatments remains a therapeutic dilemma in pediatric nephrology. To test whether the anti-CD20 monoclonal antibody rituximab may benefit these patients, we conducted an open-label, randomized, controlled trial in 31 children with idiopathic nephro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Magnasco, Alberto, Ravani, Pietro, Edefonti, Alberto, Murer, Luisa, Ghio, Luciana, Belingheri, Mirco, Benetti, Elisa, Murtas, Corrado, Messina, Giovanni, Massella, Laura, Porcellini, Maria Gabriella, Montagna, Michela, Regazzi, Mario, Scolari, Francesco, Ghiggeri, Gian Marco
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2012
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3358759/
https://ncbi.nlm.nih.gov/pubmed/22581994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2011080775
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars